A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment compared to matched...

• Country None
• organs None
• Specialty None

study in patients with actinic keratosis (an disease of the skin) with the aim to evaluate the efficacy, the safety and the pharmacokinetics (way the body absorbs, distributes, and gets ride of the drug) of LFX453 after multiple applications to the skin • To assess tolerability and safety of topical LFX453 formulations in patients with actinic keratosis (AK) • To assess efficacy of topical LFX453 formulations in treating AK compared to vehicle afte...

• Country None
• organs None
• Specialty None

A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80mg as compared to amlodipine/valsartan 5/40mg or to amlodipine 5mg once daily in elderly patients with essential hypertension not adequately controlled after four weeks on amlodipine 5mg once daily The primary objective of this trial is to evaluate the overall safety and tolerability profile of a regimen of amlodipine/valsartan 5/80 mg as compared to a regimen of amlodipine/valsartan 5/40 mg (wi...

• Country None
• organs None
• Specialty None

A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing’s disease To assess the efficacy in terms of response to pasireotide 600 μg s.c. b.i.d. and 900 μg s.c. b.i.d. independently in patients with Cushing’s disease as measured by UFC ≤1.0 X ULN from baseline after ...

• Country None
• organs None
• Specialty None

A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes and moderate or severe renal insufficiency To evaluate the safety and tolerability of vildagliptin (50 mg qd) vs. placebo in patients with T2DM and moderate or severe renal insufficiency over 24 weeks of treatment.

• Country None
• organs None
• Specialty None

randOmized stUdy using acceleromeTry to compare Sacubitril/valsarTan and Enalapril in Patients with Heart Failure (OUTSTEP-HF) To assess changes in daily non-sedentary daytime activity between baseline and after 12 weeks of treatment in sacubitril/valsartan vs. enalapril treated patients.

• Country None
• organs None
• Specialty None

A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a plus ribavirin) in treatment-naïve hepatitis C genotype 2 and 3 patients To evaluate the proportion of patients who achieve RVR with DEB025 600mg QD plus RBV 400 mg BID, DEB025 800 mg QD plus RBV 400 mg BID and DEB025 1000 mg QD treatment groups, in treatment-naïve chronic...

• Country None
• organs None
• Specialty None

A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myfortic®, Simulect® and corticosteroids in de novo adult renal transplant recipient The primary objective of the study is to compare, in stage 1, the efficacy of the first dose of AEB071 to tacrolimus, both in combination with myfortic®, Simulect®, and steroids, at 3 months after tra...

• Country None
• organs None
• Specialty None

A study to compare combination regimen with vildagliptin & metformin versus metformin in treatment-naive patients with type 2 diabetes mellitus - Demonstrate the superiority of combination of vildagliptin 50mg bid and metformin over metformin monotherapy in treatment-naive patients with T2DM by testing the hypothesis that the risk of initial ...

• Country None
• organs None
• Specialty None

A clinical research study evaluating the possibility to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients who have very small amount of leukemia cells remaining after nilotinib (Tasigna) treatment The purpose of this study is to determine the rate of successful treatment-free remission (TFR) within the first 48 weeks following cessation of treatment in patients who achieved and maintained a mol...

• Country None
• organs None
• Specialty None